Oestrogen receptor (ER)β is a multifunctional nuclear receptor that mediates the actions of oestrogenic compounds. Despite its well defined role in mediating the actions of oestrogens, a substantial body of evidence demonstrates that ERβ has a broad range of physiological functions independent of those normally attributed to oestrogen signalling. These functions can partly be achieved by the activity of several alternatively spliced isoforms that have been identified for ERβ. This short review describes structural differences between the ERβ splice variants that are known to be translated into proteins. Moreover, we discuss how these alternative structures contribute to functional differences in the context of both healthy and pathological conditions. Our review also describes the principal factors that regulate alternative RNA splicing. The alternatively spliced isoforms of ERβ are differentially expressed according to brain region, age and hormonal milieu, emphasising the likelihood that there are precise cellspecific mechanisms regulating ERβ alternative splicing. However, despite these correlative data, the molecular factors regulating alternative ERβ splicing in the brain remain unknown. We also review the basic mechanisms that regulate alternative RNA splicing and use that framework to make logical predictions about ERβ alternative splicing in the brain.
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| INTRODUCTION
Ageing represents a continuous spectrum of phenotypic and behavioural changes that are ultimately driven by an inefficient cellular functioning, thus contributing to increased cell damage over time.
Detrimental changes in cellular function include telomere shortening, increased missense/nonsense mutations, translational errors and organelle dysfunction, all of which can result in protein dysfunction and the accumulation of cytotoxic protein aggregates. Concurrent with these age-related abnormalities is an increased incidence of global alternative RNA splicing. 1 Alternative RNA splicing is heralded as a means of expanding the cellular proteome beyond the constraints of strict genetic coding. As such, it is widely considered to be both beneficial and detrimental depending on the structural and functional aspects of the alternatively expressed isoforms. In young healthy tissues, it is likely that one dominant isoform is expressed, 2 despite the availability of the molecular machinery required to achieve the expression of multiple isoforms. However, human studies demonstrate that ageing increases the incidence of alternative splicing independent of disease, thereby increasing the abundance of alternatively spliced isoforms that are expressed in a variety of tissues. One of the highest rates of alternative splicing events occurs in the brain, and an increased expression of alternatively spliced isoforms can contribute to age-related deficits in many neurobiological processes.
1,3-5
Menopause is a unique biological process in women that is concurrent with ageing. A physiological hallmark of menopause is the sharp decline in circulating levels of 17β-oestradiol (E 2 ), the primary circulating gonadal oestrogen in reproductive age women. The rapid decline of E 2 at menopause further complicates the natural aspects of ageing because E 2 is key for the maintenance of healthy organs and tissues in young women. The beneficial actions of E 2 on various organs are achieved through the high affinity binding of E 2 to its cognate receptors: oestrogen receptor (ER)α (NR3A1/ESR1) and ERβ (NR3A2/ ESR2), which function as both transcription factors and mediators of intracellular signalling cascades. [6] [7] [8] Over the past decade, many alternatively spliced transcripts for ERα and ERβ have been identified using RNA deep sequencing platforms, although few have been shown to translate into functional protein products. [9] [10] [11] [12] [13] Notably, several of these translated alternatively spliced isoforms appear to have constitutive transcriptional activity and function largely independent of ligand (i.e. E 2 ) binding. [14] [15] [16] [17] Furthermore, the concurrent age-related increase in global alternative splicing events provides a molecular framework that allows for the increased expression of these variants during this critical life transition. This intriguing hypothesis suggests that alternatively spliced forms of ER may be more biologically relevant postmenopause, whereas the dominant isoform may be more active during times of high circulating oestrogen. 18, 19 The present review focuses on the structure, function and regula- Additionally, ERβ subcellular localisation may be altered during ageing, 22 which could impact the efficacy of canonical ERβ signalling pathways. Taken together, these distinctions from ERα make ERβ, as well as its splice variants, an attractive candidate for therapeutic strategies aimed at alleviating negative symptoms associated with decreased circulating E 2 and improving cognitive function in post-menopausal women.
| ERβ: BASIC STRUCTURAL ORGANISATION
Oestrogen receptors are classified as ligand-activated transcription factors belonging to a large superfamily of nuclear receptors. 23, 24 The two primary receptors, ERα and ERβ, are encoded by distinct genes, and the mature transcripts contain eight exons. Similar to other receptors belonging to the nuclear receptor superfamily, the ERβ protein is composed of six functional domains, denoted by letters A-F, extending from the N-to C-terminus of the protein (Figure 1 ). [25] [26] [27] The N-terminal A/B domain contains the activation function-1 (AF-1) region, characterised by its cooperativity in ligand-dependent transcriptional activation and its synergistic interactions with the
C-terminal ligand-binding domain (LBD).
28 Post-translational modifications in the AF-1 region of both ERs can also initiate ligand independent transcription through the recruitment of select co-regulatory proteins. 29 An important distinction for ERβ is the apparent inhibitory effects of the AF-1 domain on its transcriptional activity. For example, experimental deletions of the ERβ AF-1 region increased dimerisation and subsequent transcriptional activity, suggesting that specific amino acid residues in this region are critical for keeping the receptor transcriptionally inactive. 30 Next, the C domain is the most highly conserved region among all members of the nuclear receptor family and contains the residues responsible for recognising specific DNA enhancer regions, such as oestrogen response elements (EREs). Stable DNA binding is achieved by the coordinated interactions of two perpendicular α-helices. 6 The first helix contains the residues responsible for DNA recognition and is situated between two zinc finger motifs, which are composed of eight cysteine residues surrounding two zinc ions. 
| ERβ SPLICE VARIANTS
Shortly after the discovery of ERβ, several alternatively spliced ERβ variants were identified in both humans and rodents. [39] [40] [41] [42] [43] Although the human and rodent ERβ splice variants differ in structure, they demonstrate remarkably similar functions. Most notably, many of the variants appear to have constitutive, or ligand independent, actions on downstream target genes. The biological consequences of this constitutive activity are predictably different for various tissue types, yet our understanding of the biological function for many of these variants is still in its infancy.
| Rodent splice variants
To date, there have been five experimentally validated functional ERβ splice variants in rodents. Here, the dominant isoform will be referred to as ERβ1. The first variant discovered in rodents was the rat ERβ2 splice variant (rERβ2). This variant contains an in-frame insertion of 54 nucleotides between exons 5 and 6, which results in a novel 18 amino acid sequence the ligand-binding domain. 39, 42, 44 The origin of these extra nucleotides was initially unclear; however, we have predicted 17 These reporter assays demonstrated that, compared to rERβ1, the ligand independent action of rERβ2 at both ERE and AP-1 promoters is lower, although rERβ1 exhibits a much larger response to ligand than rERβ2. 38 Furthermore, the observed differences in transcriptional activity were not a result of changes in DNA-binding affinity but could be explained by the inability of rERβ2
to recruit specific steroid receptor coactivators and/or differential post-translational modifications of the splice variants. 14, 17 These data provide useful mechanistic information that clarifies the differential transcriptional potential of ERβ splice variants at discrete regulatory elements; however, most endogenous gene promoters are highly complex and contain multiple regulatory regions that function in concert.
Studies using more complex promoters, such as arginine vasopressin (AVP), demonstrated that rERβ2 robustly induced AVP transcriptional activity in the presence of E 2 and 3βAdiol, a metabolite of the potent androgen dihydrotestosterone. 45 These results suggest that rERβ2 can act equivalently to ERβ1 to regulate complex gene promoters, despite its lower ligand-binding affinity, although this is likely dependent on cell type and the presence of other co-regulatory factors. Similarly, the rERβ2 LBD structure does not appear to affect its binding affinity for the ER antagonist 4-OH-tamoxifen, a phenomenon that could also be cell-type specific. 42 Next, it was discovered that exon 3 may be deleted from either rERβ1 or rERβ2, removing 39 amino acids that would normally encode the second zinc finger of the DNA-binding domain; these variants are referred to as rERβ1δ3 and rERβ2δ3, respectively. 42 They are analogous to some ERα variants, which also lack exon 3 and therefore, a portion of its DBD. The lack of a second zinc finger in the DBD results in an unstable association with EREs on gene promoters, thereby reducing or eliminating any transcriptional activation. 42 However, these variants can still tether to other DNA-bound transcription factors to elicit a physiological response, such as activation of AP-1-mediated promoter activity in the presence of E 2 . This contrasts with rERβ1 and rERβ2 because they both repress AP-1-mediated promoter activity except in the presence of tamoxifen. 33, 46 Notably, rERβ1δ3 does not show any ligand independent or ligand-dependent activity in neuronal cell lines at the rat AVP promoter, which contains a combination of AP-1 and ERE motifs. 45 The δ3 variants also organise into highly punctate subnuclear domains in response to E 2 in a manner that is distinct from that of rERβ1 or rERβ2. 46 Moreover, rERβδ3 variants colocalised with the nuclear receptor coactivator GRIP-1 in these same subnuclear punctate domains, 46 suggesting that rERβ1δ3 and rERβ2δ3
are functionally responsive to ligand through their interactions with coregulatory proteins, despite an inability to bind DNA.
Finally, exon 4 (99 amino acids) may be deleted from rERβ1, yielding a splice variant known as rERβ1δ4, resulting in deletion of the D domain of the protein. 43 This variant lacks the ability to localise to the nucleus, consistent with the deletion occurring in the nuclear localisation sequence of the hinge region. Somewhat surprisingly, rERβ1δ4 also lacks the ability to bind E 2 , which indicates that the hinge region is important for conferring a conformational structure favourable for creating a stable ligand-binding pocket. 43 Overall, rERβ1δ4 is expressed at very low levels in most brain regions tested, with the exception of the hippocampus. 43 The relatively high expression of rERβ1δ4 in the hippocampus suggests that it may play a role in memory formation or other functions regulated by the hippocampus, although these proposed functions have not been validated experimentally because rERβ1δ4 remains the least well-studied of all the rodent ERβ splice variants. (Figure 1) . 40, 41 Consequently, the LBD of the protein is the primary functional component that is altered in these splice vari-
| Human ERβ splice variants
ants. Indeed, all of the hERβ isoforms can bind to DNA and form dimers with ERβ1 in the presence of E2. 15, 16 Interestingly, heterodimers between hERβ1 and any of the other splice variants enhanced transactivation compared to hERβ1 homodimers in an ERE-dependent reporter assay in the presence of E 2 and other oestrogenic compounds in HEK293 cells. 15 However, only the full-length hERβ1 can interact with steroid receptor coactivator-1 to induce transactivation, highlighting the importance of the hERβ C-terminus for coregulatory protein binding. 15 These data suggest that only one coregulatory protein-binding site is needed in a hERβ dimer and, indeed, the absence of the second binding site appears to facilitate the actions of hERβ.
Human ERβ2 (also called hERβcx) is the most characterised of the human variants and is widely considered to function as a dominant negative receptor for ERα. 47 Molecular modelling demonstrated that hERβ2 has altered (more restricted, "tight") 3D structures in both the ligand-binding pocket and coregulator binding surface, which impairs its ability to bind ligands. 15, 16 Hence, hERβ2 has no ligand-dependent transcriptional activity, yet it retains some ligand independent activity consistent with its intact AF-1 region. 16 Structurally, hERβ4 and hERβ5 are the smallest because they completely lack helix 12 and the entire F domain, resulting in a more open conformation of the ligand-binding pocket. 41, 48 This conformation creates an unstable association with ligands and consequently lower binding affinities; however, unlike hERβ2, they are both able to bind ligands to some extent. In reporter gene assays, these variants also exhibit ligand independent activity similar to hERβ2 as a result of the intact AF-1 domain. For example, in ERE-driven reporter assays in COS-7 cells, hERβ4 and hERβ5 only demonstrated ligand independent increases in promoter activity, whereas hERβ1 appeared to drive both ligand-dependent and ligand independent promoter activity. 48 All of the apo-hERβ splice variants can constitutively activate ERE promoter activity and repress AP-1 promoter activity in reporter assays using HT-22 cells (mouse-derived hippocampal neuronal cell line), with E 2 treatment only affecting the full-length hERβ1 isoform. 16 At the more complex AVP promoter, all of the hERβ isoforms showed ligand independent repression of AP-1-mediated promoter activity, yet only hERβ1-mediated activity was abolished using the antagonist ICI 182 780. 16 Decreased ligand-binding affinities of hERβ splice variants have important implications for therapeutic strategies that employ ER agonists or antagonists because the success of these therapies must rely on the ligand-dependent activation of the dominant ERβ1 isoform.
Therefore, an increase in alternative splicing that shifts the expression profile of ERβ isoforms could render hormone-based therapies completely ineffective, or potentially amplify the effects if there is an increase in ERβ1:splice variant heterodimerisation.
To our knowledge, there is no experimental evidence available to suggest that alternative splicing of ERβ alters its heterodimerisation with ERα. However, based on the sequences of the rodent ERβ splice variants in particular, it is reasonable to predict that dimerisation with ERα would be altered. Current therapeutic interventions might not account for variations in dimerisation proficiency, although future compounds could be designed to exploit this different heterodimerisation profile and develop more precisely targeted therapeutic strategies.
| REGULATION OF ERβ ALTERNATIVE SPLICING
Alternative splicing represents a mechanism by which the cell can increase proteomic and, consequently, functional diversity from a single pre-mRNA transcript. Normally, splicing is achieved by the co- compositions, as in the case of the ERβ isoforms. As discussed previously, these receptor isoforms have functionally unique roles in both E 2 -mediated and ligand independent signalling processes compared to the dominant ERβ1 isoform. [14] [15] [16] [17] 45, 48, 55 This raises the possibility that increased alternative splicing events will significantly impact normal cellular and physiological processes, leading to an increased risk for various pathologies. Therefore, it is important to determine how ERβ alternative splicing is carefully regulated to produce cell-type specific expression profiles of ERβ isoforms, and how these expression profiles relate to diverse cellular functions.
Little is known about how the splice variants are selectively processed by specific cell types, although there is evidence to show that there are discrete spatial and temporal expression patterns for ERβ splice variants in the brain. 43, 46, 56 For example, an abundance of rERβ2 protein expression was detected in rat hypothalamic nuclei, such as the paraventricular nucleus and the supraoptic nucleus, whereas expression levels were low in the dentate gyrus. 56 Analysis of a wide variety of brain regions showed that, overall, rERβ2 was the most highly expressed rERβ splice variant in the rat brain, except in the hippocampus where rERβ1δ4 levels were most abundant. 43 These data suggest that the expression of rERβ splice variants is differentially regulated by brain region and likely coupled to specific neurological and/or behavioural functions. However, it remains to be determined whether specific rERβ splice variant expression is initiated upstream of cellular differentiation, priming the progression of neural stem cells to their respective fates, or whether specific rERβ splice variant expression is a consequence, or perhaps even an artefact, of already differentiated brain regions.
| Cis-and trans-regulatory elements
Distinct cis-regulatory sequences in the human ERβ gene confer a molecular architecture that facilitates alternative splicing in prostate and mammary glands, raising the possibility that these same molecular mechanisms contribute to brain-region specific splicing. For example, full-length hERβ transcription can be initiated from two different promoters characterised as 5′ untranslated exons, 0K and 0N, in the prostate and mammary glands. [57] [58] [59] In the prostate gland, hERβ1
and hERβ2 were predominantly transcribed from the 0N promoter, whereas hERβ5 was uniquely transcribed from the 0K promoter. 58 By contrast, both hERβ1 and hERβ5 were transcribed from the 0K promoter in benign and malignant mammary epithelial cells. 60 Depending on the site of transcription initiation, the nascent RNA transcript will include different lengths of 5′ untranslated sequences (UTRa and UTRc), which can have stable secondary structures preventing translation of the RNA product. 60 Moreover, these 5′-UTRs can dictate differential expression of ERβ splice variants through disruption or recruitment of spliceosome components. Specifically, the presence of UTRa corresponded to hERβ1 and hERβ5 expression, whereas the presence of UTRc corresponded to hERβ2 expression in MCF-7 cells. 60 Importantly, translation efficiency varied even for individual UTRs depending on cell type, suggesting that other cellular components, such as trans-acting factors, interact with the 5′-UTR sequence and dictate cell specific expression. There is also evidence that the translational efficiency of the ERβ splice variants depends, in part, on cross-talk between the 5′-UTR sequence and the length of the 3′-UTR, with shorter lengths promoting translation, despite the presence of a typically inhibitory 5′-UTRa. 61 To our knowledge, these same alternative promoter elements have not yet been defined for the rodent ERβ isoforms.
The alternative hERβ promoters are also subject to epigenetic modifications, such as DNA methylation. DNA methylation can regulate alternative splicing by recruiting methyl-binding domain proteins, such as MeCP2, that then associate with splicing factors. 62 For example, MeCP2 has been shown to associate with splicing factors such as the pre-mRNA processing factor 3, which presumably could affect splicing dynamics. 63 In ovarian carcinoma cells, an interesting correlation was observed in which the hypermethylation of the 0N promoter resulted in the decreased expression of hERβ1, hERβ2 and hERβ4 mRNA, as well as the increased expression of hERβ5 mRNA.
These findings suggest that 0N promoter hypermethylation could promote the assembly of specific spliceosome components through methyl-binding domain proteins, ultimately influencing the differential alternative splicing of hERβ. 64 However, the mechanism behind the selective enhancement of specific hERβ splice variant expression (namely hERβ1, hERβ2 and hERβ4) is still unclear because all four human splice variants, including hERβ5, are the result of similar exon exclusion events.
It is important to note that another layer of complexity is added when considering the role of trans-acting factors that could potentially interact with the abovementioned cis-regulatory elements. The molecular mechanisms of ERβ splice variant regulation in the brain are still largely uncharacterised; however, a possible explanation of the unique expression profiles can be attributed to the brain region-specific expression of RNPs (i.e. trans-acting factors) that comprise the spliceosome. Indeed, recent work in our laboratory has identified putative consensus binding sites for Nova-1, a neurone-specific RNP, upstream of the 54 bp insert in ERβ2, as well as correlative changes in Nova-1 expression with ERβ2 in several brain regions. 65 Aside from these preliminary studies, there have been no publications to date identifying specific trans-acting factors regulating ERβ alternative splicing in the brain.
| Activity-dependent splicing
Neurones are intrinsically excitable cells, and evidence suggests that 
| RNAPII kinetics
Splicing can occur co-transcriptionally and an essential component to this process is RNA polymerase II (RNAPII). 70 Various splicing factors such as SR proteins have been shown to associate with the C-terminal domain of RNAPII. 52 These RNA-binding proteins can then promote the assembly of spliceosome components to allow for the physiological processing of nascent mRNA transcripts.
Therefore, it is not surprising that altering the rate of RNAPII elongation can result in alternatively spliced mRNAs because splice sites can either be passed over or recognised depending on the pace of elongation. Generally, factors that slow down RNAPII elongation result in exon inclusion because there is a longer time interval available for the assembly of the spliceosome around a weak splice site. 71 In agreement with these findings, our laboratory previously showed that inhibiting topoisomerase I (TOP1) activity to slow splicing kinetics allowed for the aberrant recognition of weak splice sites present in the rERβ pre-mRNA. As expected, rERβ2 transcripts, with characteristic exon inclusions, were significantly increased when TOP1 was inhibited in a hypothalamic derived GT1-7 cell line. 
| Ageing and E 2 deprivation
The number of alternative splicing events in the human brain have been shown to increase with age; therefore, it can be speculated that ERβ splice variant expression is also increased during the ageing process. 1 Consistent with this hypothesis, our laboratory demonstrated that rERβ2 expression was significantly increased in the hypothalamus of 18-month-old (aged) female rats compared to their 3-month-old (young) counterparts. 72 However, the other rat ERβ splice variants were not detected in significant concentrations in the brain regions tested and therefore it cannot be concluded that all ERβ splice variants increase with age. Additionally, another layer of complexity must be considered in females because ageing is closely associated with the onset of menopause, during which there is a loss of circulating E 2 . Interestingly, age and E 2 deprivation together have been shown to alter rERβ2 expression in a brain-region specific manner, suggesting that the normal ageing process and the absence of E 2 could both have independent and coordinated effects on the alternative splicing of ERβ. 72 These findings were also consistent with a separate study showing that the deprivation of E 2 corresponded to the increased expression of rERβ2 in both the rat brain and circulating white blood cells. 73 Moreover, increased rERβ2 expression correlated with a reduction in the effectiveness of E 2 treatment on depressive behaviours using a forced swim test paradigm. 73 Taken together, these data suggest that the presence of E 2 inhibits the expression of rERβ2 splice variants in the brain;
however, the mechanism for how this occurs is still unclear. with an increased expression of several oncogenes. 11 An enrichment of hERβ5 was also observed in patients with HER2 positive and triplenegative breast cancer and predicted poorer prognostic outcomes. 74 By contrast, another study reported that increased hERβ2 and hERβ5 expression was correlated with a better relapse-free survival rate in 105 post-menopausal breast cancer patients; however, that study did not report the HER2 status in those tumours, suggesting that, even within breast cancers, there are context specific functions of ERβ splice variants. 75 The development of malignant prostate tumors also revealed a dramatic shift in the ratio of the dominant hERβ1 isoform to its alternatively spliced variants. Specifically, the expression of hERβ1, which is normally anti-proliferative in prostate tissue, gradually declines and then becomes undetectable coincident with an increased expression of hERβ2 during the progression of prostate cancer.
| ERβ SPLICE VARIANTS AND AGE-RELATED DISEASE

76,77
Moreover, stable overexpression of hERβ2 in prostate tumour-derived PC-3 cells resulted in the increased expression of several oncogenic genes. 78 Taken together, these data suggest that some hERβ splice variants can increase oncogene expression leading to carcinogenesis in certain tissues.
Interestingly, the hormonal milieu appears to also play a role in determining the carcinogenic potential of hERβ splice variants. For example, hERβ2 was expressed in 100% of patients with papillary thyroid cancers (PTC) and its expression was correlated with increased Ki-67 and vascular endothelial growth factor expression in both post-menopausal women and men (i.e. low E 2 ). 18 By contrast, hERβ2 expression was lower in pre-menopausal women with PTC and concurrent lymph node metastasis, suggesting that higher E 2 levels prevented the progression of PTC by regulating the expression of hERβ2. 18 These data are consistent with those from our laboratory and others demonstrating increased expression of ERβ2 in the brain of aged ovariectomised female rats (i.e. low E 2 ) and the subsequent decrease of ERβ2 following E 2 treatment. 72, 73 Overall, evidence suggests that there is a correlation between the expression of ERβ alternative splice variants and cancer progression. Although, to our knowledge, no studies have demonstrated a direct causal role of ERβ splice variants in tumour development. 
| CONCLUSIONS
